Pacific Shuanglin Bio-pharmacy Co., LTD

000403

CNE000000F14

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
26.7 ^CNY	-0.34%		-2.23%	-1.98%

May. 23	Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin	MT
May. 22	Pacific Shuanglin Bio-pharmacy Co., LTD Approves Cash Dividend for the Year 2023	CI

Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.

July 21, 2023 at 12:00 pm EDT

From July 1, 2023 to July 20, 2023, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 1,968,378 shares, representing 0.27% for CNY 40.1 million under the buyback announced on September 1, 2022.

Latest news about Pacific Shuanglin Bio-pharmacy Co., LTD

Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin	May. 23	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Approves Cash Dividend for the Year 2023	May. 21	CI
Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License	May. 09	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Pacific Shuanglin Bio-pharmacy's 2023 Profit Jumps 4% Despite Lower Revenue; Shares Rise 4%	Apr. 15	MT
Pacific Shuanglin Bio-pharmacy's Profit Seen More Than Doubling in Q1; Shares Up 3%	Apr. 15	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
Pacific Shuanglin Bio-pharmacy Co., LTD announced a financing transaction	Feb. 22	CI
Pacific Shuanglin Bio-pharmacy Unit Gets Nod to Trial Human Coagulation Factor IX	Nov. 06	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Approves Board Appointments	23-10-26	CI
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-18	CI
Pacific Shuanglin Bio-pharmacy Obtains Another Blood Collection License	23-09-21	MT
Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Pacific Shuanglin Bio-pharmacy Obtains Blood Plasma Collection License	23-08-08	MT
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.	23-07-21	CI
Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback announced on September 1, 2022 has expired with 1,968,378 shares, representing 0.27% for CNY 40.1 million.	23-07-19	CI
Pacific Shuanglin Bio-Pharmacy Co., Ltd Announces Final Dividend Implementation on A Shares for the Year 2022, Payable on July 20, 2023	23-07-14	CI
Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.	23-07-03	CI
Pacific Shuanglin Bio-pharmacy's Unit Gets Permit to Operate Two Plasma Hubs	23-05-26	MT
Pacific Shuanglin Bio-Pharmacy Co., Ltd Approves 2022 Profit Distribution Plan	23-05-23	CI
Gongqingcheng Shengbang Yinghao Investment Partnership (Limited Partnership) completed the acquisition of 20.99% stake in Pacific Shuanglin Bio-pharmacy Co., LTD from Hangzhou Zhemintou Tianhong Investment Partnership Enterprise (LP) and Zhejiang Private Enterprise United Investment Co., Ltd.	23-05-22	CI
Pacific Shuanglin Bio-pharmacy Registers Blood Clotting Drug	23-05-18	MT
Pacific Shuanglin Bio-pharmacy Signs Drug Supply, Distribution Deal With Brazil’s Hypera Pharma	23-05-05	MT
Pacific Shuanglin Bio-Pharmacy Co., Ltd Announces Final Cash Dividend (Tax Included) for 2022	23-05-04	CI
Pacific Shuanglin Bio-Pharmacy Posts Double-Digit Drop in Q1 Earnings on Lower Sales	23-05-01	MT

Chart Pacific Shuanglin Bio-pharmacy Co., LTD

Duration

Period

Chart Pacific Shuanglin Bio-pharmacy Co., LTD

More charts

Company Profile

Pacific Shuanglin Bio pharmacy Co Ltd, formerly Southern Shuanglin Bio-pharmacy Co Ltd, formerly Zhenxing Biopharmaceutical & Chemical Co., Ltd., is a China-based company mainly engaged in the research, development, production and sales of blood products. The Company's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The Company mainly operates its business in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Pacific Shuanglin Bio-pharmacy Co., LTD

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.7 CNY

Average target price

34.4 CNY

Spread / Average Target

+28.84%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD	-1.98%	2.69B
CSL LIMITED	-2.00%	90.02B
SAMSUNG BIOLOGICS CO.,LTD.	-1.18%	39.15B
BIOGEN INC.	-15.83%	31.71B
UCB	+62.86%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-21.68%	14.34B
INCYTE CORPORATION	-8.73%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.05%	11.18B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.69%	10.97B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.94B

Biopharmaceuticals

Pacific Shuanglin Bio-pharmacy Co., LTD

Equities

000403

CNE000000F14

Pharmaceuticals

Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.

Latest news about Pacific Shuanglin Bio-pharmacy Co., LTD

Chart Pacific Shuanglin Bio-pharmacy Co., LTD

Company Profile

Income Statement Evolution

Ratings for Pacific Shuanglin Bio-pharmacy Co., LTD

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals